New Data Presented on Duvyzat (Givinostat) for Treatment of Duchenne Muscular Dystrophy at 2025 World Muscle Society Congress
Italfarmaco announced that additional data on givinostat for the treatment of Duchenne muscular dystrophy (DMD) are being presented at the 30th annual International Congress...
Form Bio and Cure Rare Disease Partner to Accelerate Genetic Medicine Development, Advancing CRD’s Duchenne Muscular Dystrophy Program
Form Bio, a leader in AI-powered genetic medicine development and genome engineering, announced a strategic partnership with Cure Rare Disease (CRD), a nonprofit biotechnology...
Health Canada Approves AGAMREE (vamorolone) as the First Treatment for Duchenne Muscular Dystrophy in Canada
Kye Pharmaceuticals announced that Health Canada has approved AGAMREE (vamorolone) for the treatment of Duchenne Muscular Dystrophy (DMD) in boys age 4 and older....
Tevard Biosciences Presents Data Demonstrating Production of Full-Length Protein with tRNA-Based Therapy for Duchenne Muscular Dystrophy
Tevard Biosciences announced the presentation of new preclinical data showing potent restoration of full-length functional proteins in models of Duchenne muscular dystrophy (DMD) and...
Dyne Therapeutics Receives Orphan Drug Designation in Japan for DYNE-251 in Duchenne Muscular Dystrophy
Dyne Therapeutics announced that the Ministry of Health, Labour and Welfare (MHLW) in Japan has granted Orphan Drug designation for DYNE-251 in individuals with...